Literature DB >> 32592103

CYP1A2 rs762551 polymorphism and risk for amyotrophic lateral sclerosis.

Vasileios Siokas1, Emmanouil Karampinis1, Athina-Maria Aloizou1, Alexios-Fotios A Mentis2,3, Panagiotis Liakos4, Dimitra Papadimitriou5, Ioannis Liampas1, Grigorios Nasios6, Dimitrios P Bogdanos7, Georgios M Hadjigeorgiou1,8, Efthimios Dardiotis9.   

Abstract

BACKGROUND: Genetic variability is considered to confer susceptibility to amyotrophic lateral sclerosis (ALS). Oxidative stress is a significant contributor to ALS-related neurodegeneration, and it is regulated by cytochromes P450 (CYPs), such as CYP1A2; these are responsible for the oxidative metabolism of both exogenous and endogenous substrates in the brain, subsequently impacting ALS. The function of CYP1A2 is largely affected by genetic variability; however, the impact of CYP1A2 polymorphisms in ALS remains underinvestigated.
OBJECTIVE: This study aims to examine the possible association of ALS with the CYP1A2 rs762551 polymorphism, which codes for the high inducibility form of the enzyme.
METHODS: One hundred and fifty-five patients with sporadic ALS and 155 healthy controls were genotyped for the CYP1A2 rs762551. Statistical testing for the association of CYP1A2 rs762551 with risk for ALS was performed using SNPstats.
RESULTS: The CYP1A2 rs762551 C allele was associated with a decreased risk of ALS development. In the subgroup analysis according to the ALS site of onset, an association between CYP1A2 rs762551 and limb and bulbar onset of ALS was shown. Cox proportional-hazard regression analyses revealed a significant effect of the CYP1A2 rs762551 on the age of onset of ALS.
CONCLUSIONS: Based on our results, a primarily potential link between the CYP1A2 rs762551 polymorphism and ALS risk could exist.

Entities:  

Keywords:  ALS; CYP1A2; Oxidative stress; Polymorphism; rs762551

Mesh:

Substances:

Year:  2020        PMID: 32592103     DOI: 10.1007/s10072-020-04535-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  39 in total

Review 1.  Amyotrophic Lateral Sclerosis.

Authors:  Robert H Brown; Ammar Al-Chalabi
Journal:  N Engl J Med       Date:  2017-07-13       Impact factor: 91.245

Review 2.  Genetic polymorphisms in amyotrophic lateral sclerosis: Evidence for implication in detoxification pathways of environmental toxicants.

Authors:  Efthimios Dardiotis; Vasileios Siokas; Maria Sokratous; Zisis Tsouris; Amalia Michalopoulou; Athina Andravizou; Metaxia Dastamani; Styliani Ralli; Marco Vinceti; Aristidis Tsatsakis; Georgios M Hadjigeorgiou
Journal:  Environ Int       Date:  2018-04-17       Impact factor: 9.621

3.  The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis.

Authors:  Efthimios Dardiotis; Athina-Maria Aloizou; Vasileios Siokas; George P Patrinos; Georgia Deretzi; Panayiotis Mitsias; Michael Aschner; Aristidis Tsatsakis
Journal:  J Mol Neurosci       Date:  2018-11-10       Impact factor: 3.444

4.  Long-term survival in amyotrophic lateral sclerosis: a population-based study.

Authors:  Elisabetta Pupillo; Paolo Messina; Giancarlo Logroscino; Ettore Beghi
Journal:  Ann Neurol       Date:  2014-02-24       Impact factor: 10.422

Review 5.  Decoding ALS: from genes to mechanism.

Authors:  J Paul Taylor; Robert H Brown; Don W Cleveland
Journal:  Nature       Date:  2016-11-10       Impact factor: 49.962

Review 6.  Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention.

Authors:  Mauro Cozzolino; Maria Grazia Pesaresi; Valeria Gerbino; Julian Grosskreutz; Maria Teresa Carrì
Journal:  Antioxid Redox Signal       Date:  2012-04-30       Impact factor: 8.401

Review 7.  Pathogenesis of amyotrophic lateral sclerosis.

Authors:  Sarah Morgan; Richard W Orrell
Journal:  Br Med Bull       Date:  2016-07-22       Impact factor: 4.291

8.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

Authors:  D R Rosen; T Siddique; D Patterson; D A Figlewicz; P Sapp; A Hentati; D Donaldson; J Goto; J P O'Regan; H X Deng
Journal:  Nature       Date:  1993-03-04       Impact factor: 49.962

9.  TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis.

Authors:  Edor Kabashi; Paul N Valdmanis; Patrick Dion; Dan Spiegelman; Brendan J McConkey; Christine Vande Velde; Jean-Pierre Bouchard; Lucette Lacomblez; Ksenia Pochigaeva; Francois Salachas; Pierre-Francois Pradat; William Camu; Vincent Meininger; Nicolas Dupre; Guy A Rouleau
Journal:  Nat Genet       Date:  2008-03-30       Impact factor: 38.330

10.  ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS.

Authors:  Christopher Crockford; Judith Newton; Katie Lonergan; Theresa Chiwera; Tom Booth; Siddharthan Chandran; Shuna Colville; Mark Heverin; Iain Mays; Suvankar Pal; Niall Pender; Marta Pinto-Grau; Ratko Radakovic; Christopher E Shaw; Laura Stephenson; Robert Swingler; Alice Vajda; Ammar Al-Chalabi; Orla Hardiman; Sharon Abrahams
Journal:  Neurology       Date:  2018-09-12       Impact factor: 9.910

View more
  7 in total

Review 1.  Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes.

Authors:  Yeo-Jung Kwon; Sangyun Shin; Young-Jin Chun
Journal:  Arch Pharm Res       Date:  2021-01-23       Impact factor: 4.946

2.  Lack of association between TREM2 rs75932628 variant and amyotrophic lateral sclerosis.

Authors:  Vasileios Siokas; Athina-Maria Aloizou; Ioannis Liampas; Zisis Tsouris; Alexios-Fotios A Mentis; Grigorios Nasios; Dimitra Papadimitriou; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  Mol Biol Rep       Date:  2021-04-07       Impact factor: 2.316

Review 3.  A novel variant in DYNC1H1 could contribute to human amyotrophic lateral sclerosis-frontotemporal dementia spectrum.

Authors:  Alexios-Fotios A Mentis; Dimitrios Vlachakis; Eleni Papakonstantinou; Ioannis Zaganas; George P Patrinos; George P Chrousos; Efthimios Dardiotis
Journal:  Cold Spring Harb Mol Case Stud       Date:  2022-03-24

4.  zzm321990 ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinson's Disease.

Authors:  Vasileios Siokas; Athina-Maria Aloizou; Zisis Tsouris; Ioannis Liampas; Panagiotis Liakos; Daniela Calina; Anca Oana Docea; Aristidis Tsatsakis; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  J Clin Med       Date:  2021-01-20       Impact factor: 4.241

5.  Gene prediction of aging-related diseases based on DNN and Mashup.

Authors:  Junhua Ye; Shunfang Wang; Xin Yang; Xianjun Tang
Journal:  BMC Bioinformatics       Date:  2021-12-17       Impact factor: 3.169

6.  Lack of an association between SCFD1 rs10139154 polymorphism and amyotrophic lateral sclerosis.

Authors:  Vasileios Siokas; Athina-Maria Aloizou; Ioannis Liampas; Christos Bakirtzis; Grigorios Nasios; Konstantinos Paterakis; Markos Sgantzos; Dimitrios P Bogdanos; Demetrios A Spandidos; Aristidis Tsatsakis; Panayiotis D Mitsias; Efthimios Dardiotis
Journal:  Mol Med Rep       Date:  2022-03-02       Impact factor: 2.952

7.  MOBP rs616147 Polymorphism and Risk of Amyotrophic Lateral Sclerosis in a Greek Population: A Case-Control Study.

Authors:  Ioannis Liampas; Vasileios Siokas; Athina-Maria Aloizou; Christos Bakirtzis; Zisis Tsouris; Anastasia Nousia; Grigorios Nasios; Dimitra Papadimitriou; Panagiotis Liakos; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  Medicina (Kaunas)       Date:  2021-12-07       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.